๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HR-positive/HER2-negative Breast Cancer

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Abemaciclib, Radiation Therapy Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site๐Ÿ“ Orange University of California, Irvine ยท Tests: Fulvestrant, Anastrozole, Abemaciclib Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy NCT07137871Phase 11 site๐Ÿ“ San Antonio The University of Texas Health Science Center at San Antonio ยท Tests: Avasopasem Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer NCT07358377Phase 16 sites๐Ÿ“ Bowral๐Ÿ“ Sydney๐Ÿ“ Sydney Atridia Pty Ltd. ยท Tests: HRS-6209 Capsules and fulvestrant injection Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer NCT05878314n/a1 site๐Ÿ“ Tรผbingen University Hospital Tuebingen RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Dalpiciclib, Endocrine therapy A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Genor Biopharma Co., Ltd. ยท Tests: GB491 combined with Letrozole, Placebo combined with Letrozole A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Beverly Hills Puma Biotechnology, Inc. ยท Tests: Alisertib, Endocrine therapy Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) NCT06977893Phase 313 sites๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites๐Ÿ“ St Leonards๐Ÿ“ Nedlands๐Ÿ“ Perth RayzeBio, Inc. ยท Tests: RYZ211/212 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer NCT05982093Phase 215 sites๐Ÿ“ Badalona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Vilanova SOLTI Breast Cancer Research Group ยท Tests: Elacestrant, Triptorelin, Tamoxifen 20 mg SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites๐Ÿ“ Fort Worth๐Ÿ“ Houston๐Ÿ“ San Antonio Antares Therapeutics, Inc ยท Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Port Saint Lucie Regor Pharmaceuticals Inc. ยท Tests: RGT-419B, RGT-419B in combination with hormonal therapy Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer NCT04263298Phase 313 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Herui Yao ยท Tests: Fulvestrant, Capecitabine Oral Product A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy